
Actio Biosciences
Actio Biosciences was founded on an understanding that developing new drugs for rare diseases can inform novel treatment approaches for common diseases.
Date | Investors | Amount | Round |
---|---|---|---|
investor investor investor investor investor | €0.0 | round | |
* | $66.0m | Series B | |
Total Funding | 000k |
Related Content
Actio Biosciences is a biotechnology startup that focuses on the development of new drugs for rare diseases. The company operates in the pharmaceutical industry, specifically in the niche of rare disease drug development. Their business model is based on the understanding that studying and developing treatments for rare diseases can lead to innovative treatment approaches for more common diseases.
The company's primary clients are healthcare providers and patients suffering from rare diseases. They also collaborate with joint marketing partners and other third parties, which could include other pharmaceutical companies, research institutions, and healthcare organizations.
Actio Biosciences makes money by developing and selling their proprietary drugs. They own the trademarks to their product names, which suggests that they have a portfolio of unique drugs. The company also seems to be open to partnerships and joint ventures, which could provide additional revenue streams.
It's important to note that the company emphasizes transparency and patient education. They make an effort to clearly explain what information they collect from patients and how they use it. They also encourage patients to discuss treatment options with their healthcare providers, indicating a patient-centric approach to their business.
Keywords: Biotechnology, Pharmaceutical Industry, Rare Diseases, Drug Development, Healthcare Providers, Patient-Centric, Transparency, Joint Ventures, Proprietary Drugs, Patient Education.